Great businesses at fair prices — here's why each makes the list.
…and 349 more buy candidates in the full briefing.
41 name(s) sliding toward Avoid:
Value $107,525 ▲ +7.5% since 2026-07-16 · ▼ -$536 (-0.5%) since yesterday · S&P +1.7% · Cash $3,897
| Stock | Held | Price | Today | Since buy | Grade |
| CF | 83 sh | $125.70 | ▼ -1.2% | -3.0% | 89 |
| EOG | 78 sh | $144.84 | ▼ -1.4% | +7.5% | 88 |
| FHI | 156 sh | $65.09 | ▼ -0.5% | +8.6% | 91 |
| HIG | 73 sh | $139.86 | ▲ +1.2% | +2.3% | 90 |
| INTU | 33 sh | $345.88 | ▼ -3.2% | +17.3% | 87 |
| LOPE | 69 sh | $148.77 | ▼ -0.2% | +3.9% | 90 |
| LULU | 85 sh | $116.35 | ▼ -1.7% | -2.1% | 88 |
| NBIX | 58 sh | $156.59 | ▲ +2.1% | -8.7% | 89 |
| PRI | 31 sh | $301.09 | ▲ +1.1% | -3.7% | 93 |
| RMD | 49 sh | $235.69 | ▼ -0.4% | +16.2% | 84 |
Fictional money · prices update daily · a live test of whether the picks actually work.
Does the grading actually work? Two honest halves — a backtest on past data, and the real live record as it ripens. It reports the truth even when that's “not enough data yet.”
Reconstructed 319 graded moments across 150 companies (a sample of 150 names), then measured what each actually returned over the next 12 months.
Do higher grades earn better returns?
| Grade | Names | 12-mo return | vs S&P |
| A (80-100) | 43 | +13.5% | -0.5% |
| B (65-79) | 161 | +11.9% | -3.6% |
| C (50-64) | 91 | +12.9% | -1.7% |
| D-F (<50) | 24 | +41.0% | +27.2% |
→ higher grades did WORSE here (gap 27.5 pts) ⚠️
27 snapshot(s) since 2026-07-06, none ripe yet — first 6-month check ~2027-01-06.
Backtest limits: ~5 years back, surviving companies only, restated statements — a strong first read, not gospel. The live record is the hindsight-free gold standard and strengthens every month. Refreshed 2026-08-23. Educational only — not financial advice.
What the agent actually read today, in plain English. News is context alongside the grade — it never overrides it.
Earnings Sept 3 + outlook-cut warning. UBS warned that Lululemon is expected to cut its fiscal 2026 outlook when it reports Q2 earnings on Sept 3, citing weak sales in both the U.S. and China. Management's own guidance already calls for revenue to decline 2-3% and net income to drop 42-43%. The stock is down 49% from its all-time high and trades at just $116 (market cap ~$13B). KeyBanc reiterated its rating amid "soft U.S. trends." On the positive side, a new CEO (Heidi O'Neill, former Nike executive) starts Sept 8, which some see as a potential reset for sentiment.
Michael Burry is long. Scion Asset Management's Michael Burry called LULU stock "screaming cheap" and has been buying, while shorting Nvidia heading into its own earnings — a contrarian signal, though Burry's track record on individual stock calls is mixed.
Dick's Sporting Goods dragged the sector. DECK, LULU, and other athletic/apparel names fell together after Dick's reported weak earnings and warned about excess inventory forcing heavy discounting across the sector. This is a sector headwind, not company-specific.
What it means: The grade (88.2) is driven by strong profitability and brand quality, but the near-term news is cautious — a guidance cut on Sept 3 would not be a surprise since it's already widely expected. The real question is whether the new CEO can reverse the trend over the next year. Watch the earnings call closely.
Groundbreaking on $3.7B blue ammonia mega-plant. CF Industries, together with Japan's JERA (35%) and Mitsui (25%), broke ground on "Blue Point One" in Modeste, Louisiana — expected to be the world's largest ammonia plant when completed in 2029, producing 1.4 million metric tons per year. CF holds 40% of the joint venture. Linde is investing $400M+ in supporting infrastructure. The plant will capture 98% of CO2 emissions, positioning CF as a leader in low-carbon ammonia for both agriculture and emerging energy uses. This is a genuine long-term catalyst — it diversifies CF beyond traditional fertilizer and taps the growing clean-energy ammonia market.
Downgrade from Freedom Broker on near-term nitrogen price softness, though this is a smaller brokerage and the concern (commodity price cycles) is well-known in the fertilizer space.
What it means: The Blue Point One groundbreaking is the most material news here — a real, large-scale strategic investment. The downgrade on nitrogen prices is worth noting but doesn't change the long-term story. Grade and news are aligned.
Blowout Q2: revenue +39%, EPS +73%, guidance raised. Neurocrine reported $959M in Q2 revenue (vs. $901.5M consensus), and adjusted EPS of $2.85 (vs. $2.26 expected). The beat was broad: Ingrezza (movement-disorder drug) did $716M, Crenessity $184M, and the newly launched Vykat XR added $54M. Management raised full-year Ingrezza sales guidance to $2.825-$2.875B (from $2.7-$2.8B), roughly 13% growth.
Pipeline catalysts ahead. Management expects ~10 clinical readouts in 2027, providing multiple shots on goal beyond Ingrezza. Analysts at Seeking Alpha noted the company is a "house full of options." Still, Ingrezza remains the dominant revenue driver, and post-marketing safety events for Vykat XR bear watching.
What it means: This is one of the cleanest news-grade alignments in today's packet. Strong beat, raised guidance, pipeline optionality — all consistent with the 89.3 grade. The main risk is concentration in Ingrezza and the premium valuation (17.6x forward earnings vs. peers).
Fairly valued on earnings, strong returns. An analysis found PRI trades at 11.7x P/E (vs. insurance peer average of 13.2x), roughly in line with its estimated fair value of 11.4x — not cheap, not expensive. Five-year total return is 113%.
Mixed fundamentals. The investment & savings business is booming (segment revenue +21%, pretax income +31% in Q2, client assets at a record $140B). But the core Term Life business is struggling — policies issued fell 12% YoY, and the sales force contracted 3% with new life licenses down 15%. EPS is still expected to grow 9.5% for 2026 ($25.09/share), and capital returns are strong ($135M/quarter in buybacks, dividend raised 15%).
Insider sale. President Peter Schneider sold 1,800 shares ($563K) at $312.65 — about 18% of his direct holdings. Could be routine profit-taking (stock is up 16% YTD), but worth noting.
What it means: The 92.8 grade reflects Primerica's exceptional financial health and profitability. The life-insurance weakness is a real headwind, but the investment business is more than compensating for now. The insider sale is small and likely routine. Grade and news are consistent.
Q2 revenue +8.1%, strongest in peer group. Hartford reported $7.26B in revenue, in line with expectations and the fastest growth among multi-line insurers (vs. Chubb, AIG, Kemper). Net premiums were solid, though book value per share missed estimates. The stock dipped 2.2% post-earnings.
Institutional buying wave. Multiple large institutions added HIG positions recently (Legal & General, Man Group, Commerce Bank, CIBC, among others). This often signals institutional confidence but is backward-looking (13F filings reflect positions from weeks ago).
UC Berkeley partnership. Hartford partnered with UC Berkeley's Bakar Labs to support emerging companies in energy and materials — a minor but forward-looking initiative.
What it means: Solid, unexciting quarter — revenue growth is strong, the miss on book value is worth watching but not alarming. The 90.3 grade reflects Hartford's consistent profitability and financial strength, which the Q2 results support.
Upgraded to Zacks Strong Buy. The upgrade was driven by a 7.8% increase in consensus earnings estimates over the past three months. FHI is one of the nation's largest money-market fund managers.
Capital returns look sustainable. Dividend raised 11.8% in April (to $0.38/quarter), with a low 28% payout ratio and 9% annualized dividend growth over 5 years. Strong balance sheet: $481M in cash vs. $349M in long-term debt. Active buyback programs with ~2.3M shares remaining. The company also grew via acquisition — an 80% stake in FCP Fund Manager added ~$3.2B in real estate assets.
Insider selling. EVP/CLO Peter Germain sold shares (~$276K), a relatively small amount.
What it means: FHI is quietly executing — growing dividends, buying back stock, making selective acquisitions, all funded comfortably. The Zacks upgrade reflects improving earnings estimates. Grade and news align well. The insider sale is small.
Strong Q2 but downgraded by Capital One. EOG posted adjusted EPS of $5.07 (+118.5% YoY), with free cash flow of $2.8B and total production up 24.4%. Crude realized prices were $98.15/barrel. The company targets 5% oil production growth and returns at least 70% of free cash flow to shareholders. It trades at 11.7x P/E, below the oil/gas peer average of 13x.
Capital One downgrade pressured the stock, though the specific reasoning appears to be concern about 2027 earnings declining ($14.12 vs. $16.87 in 2026) as commodity prices normalize.
What it means: The fundamentals are strong — big earnings, big cash flow, shareholder-friendly returns. The downgrade reflects the perennial E&P question: can this last if oil prices soften? The grade (87.8) accounts for commodity-cycle risk through the valuation and stability pillars. Zacks rates it a Hold; MarketMind's grade is more favorable because the financial health and profitability scores are excellent.
SEC 8-K filing (Aug 21). Grand Canyon Education filed a material-event 8-K with the SEC. The filing itself returned a 403 error when I tried to read it directly, so I cannot confirm the specific content. Based on timing (mid-August) and the company's history, this could be related to an executive change, a financial update, or a regulatory matter — but I don't want to guess without reading the actual document.
Institutional buying. BlackRock, Bank of Nova Scotia, and Algert Global all took new or increased positions. The stock gapped down on Aug 25 (per MarketBeat) but specifics on why were not available in the articles.
What it means: The SEC 8-K is the one piece I couldn't verify — worth checking directly on EDGAR if you want to know what it says. The institutional buying is routine. The grade (89.6) reflects LOPE's strong profitability and growth in the for-profit education space.
Quarterly dividend declared. $0.54/share, payable Oct 15. This is a continuation of the regular dividend — no change, no surprise.
No company-specific news of note. The other RJF headlines were about Raymond James' analyst coverage of other companies (upgrading AMD, raising NVDA's price target), institutional position changes, and stock-vs-peers comparisons. None represent a catalyst for RJF itself.
What it means: Quiet week for Raymond James. The grade (88.5) reflects strong financials and profitability in the wealth-management/brokerage space. No news to change the picture.
Stock fell ~3.8% on sector headwinds, not company news. Dick's Sporting Goods' weak earnings warning about excess inventory and forced discounting across athletic retail dragged the whole sector down — including DECK, Nike, Under Armour, and Levi's. This was not a Deckers-specific issue.
Motley Fool sees a potential double by 2030. The bull case: DECK trades at just 13x forward earnings (down from 24x two years ago), revenue topped $1B for the first time, HOKA brand is expected to grow in the low-double-digit range, and international expansion is outpacing the U.S. The argument is that if the valuation normalizes and HOKA keeps growing, shares could roughly double.
What it means: The sell-off looks like guilt-by-association rather than a fundamental problem at Deckers. The HOKA growth story remains intact. The grade (87.3) reflects strong profitability and growth; the low valuation multiple is why the valuation pillar scores well too. Worth watching Dick's inventory warning for whether it spreads to Deckers' own channels.
- LOPE SEC 8-K filing (sec.gov): returned a 403 Forbidden error. The content of this material-event filing is unverified.
- Google News redirect links (news.google.com/rss/articles/...): these typically redirect to the actual publisher, but most are duplicates of articles already read via Yahoo Finance or Motley Fool.
This digest is research assistance, not financial advice. All grades are from MarketMind's quantitative scoring system. News is shown alongside the grade — it does not override it.
MarketMind is a personal, educational stock-research tool. Every morning it screens roughly 900 large- and mid-cap U.S. companies, grades each one from 0–100 on five research-backed pillars — financial health, profitability, growth, valuation, and moat — and surfaces the businesses that look strong and reasonably priced.
The idea it rests on: over the long run, a stock's price follows the company's profits. So rather than chasing hype, MarketMind looks for great businesses at fair prices and lets time do the work.
It also runs a Paper Fund — a fictional $100,000 that automatically follows the tool's own Buy ratings — so you can watch, over time, whether the picks actually work. It's pretend money: nothing here is ever bought or sold for real.
Built with free public data · refreshed every morning at 7:00 AM U.S. Central time.